Solara Active Pharma Sciences Ltd
Pharmaceuticals & Biotechnology | Small Cap
Solara Active Pharma Sciences Ltd, operating in the Healthcare Services sector, shows a mixed financial performance. The company demonstrates strong solvency, indicating a low level of debt relative to its assets and equity. Profitability metrics present a varied picture, with good gross profit and operating margins, but concerning returns on equity and net margins which needs to be addressed. Growth metrics are highly variable, with strong earnings per share growth offset by declines in revenue and asset growth. The company's liquidity position appears strained, so improvements are needed to improve financial flexibility. While efficiency ratios also show need for improvement, the company's solvency ratios are strong.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio6.00
- Financial Ratio2.20
- Profitability Ratio6.60
- Efficiency Ratio2.67
- Coverage Ratio2.00
- Solvency Ratio10.00
- Liquidity Ratio3.08
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentWeak
- 1 HourBearish
- 2 HoursBearish
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekBullish
- 1 MonthNeutral
Solara Active Pharma Sciences Ltd, operating in the Healthcare Services sector, shows a mixed financial performance. The company demonstrates strong solvency, indicating a low level of debt relative to its assets and equity. Profitability metrics present a varied picture, with good gross profit and operating margins, but concerning returns on equity and net margins which needs to be addressed. Growth metrics are highly variable, with strong earnings per share growth offset by declines in revenue and asset growth. The company's liquidity position appears strained, so improvements are needed to improve financial flexibility. While efficiency ratios also show need for improvement, the company's solvency ratios are strong.
Overall Valuation Score
P/E RATIO (TTM)
-375.40
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
-274.68
P/B RATIO
1.63
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
1.33
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
10.15
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹563.1 as on Jun 20, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The growth metrics present a mixed picture. While earnings per share and net income have shown strong growth, revenue and asset growth rates are declining. This suggests that improvements in profitability are driven by cost management rather than top-line expansion. The company should work towards higher revenue growth.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -21.58 | 13.88 | -10.73 | -0.39 | 6.62 |
| Operating Profit Growth Rate | -79.02 | 65.43 | -170.9 | -316.84 | -9.22 |
| Earnings Per Share (EPS) Growth | -126.2 | -61.85 | 2458.66 | -100.13 | -1466.67 |
| Asset Growth Rate | 12.66 | -1.56 | -18.9 | -5.06 | 4.53 |
| Net Income Growth Rate | -126.24 | -62.07 | 2477.27 | -100.18 | -800 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The financial metrics indicate challenges in profitability and shareholder returns. Negative adjusted and cash earnings per share suggest losses. The book value per share is low, while dividend per share is minimal. These issues are offset by strong solvency ratios. The company needs to focus on improving its financial metrics.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | -15 | -6.11 | -113.33 | 0.25 | -0.22 |
| Cash Earnings Per Share (Cash EPS) | 15 | 24.72 | -128.89 | 25 | 20.67 |
| Book Value Per Share | 423.61 | 416.67 | 259.44 | 273.5 | 278.44 |
| Dividend Per Share (DPS) | 0 | 2.26 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 209 | 110 | 40 | 40 | 52 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The profitability ratios indicate a mixed performance. While gross profit and operating margins are healthy, returns on equity and net margins are concerning. The company demonstrates an ability to control costs but struggles to convert revenue into net profit. Company needs to focus on increasing the profitability.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | -2.44 | 1.59 | -15.36 | 8.33 | 6.36 |
| Return on Capital Employed (ROCE) | 0 | 2 | -9 | 6 | 5 |
| Return on Equity (ROE) | -3.8 | -1.47 | -60.71 | 0.09 | -0.56 |
| Return on Assets (ROA) | 2.75 | 4.62 | -4.04 | 9.23 | 8.02 |
| Operating Margin | 6.39 | 9.28 | -7.37 | 16.04 | 13.66 |
| Net Margin | -4.57 | -1.52 | -43.99 | 0.08 | -0.51 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
Efficiency ratios suggest the company is not effectively utilizing its assets. Low turnover ratios for fixed assets, inventory, and receivables indicate slower conversion into sales. High days sales in inventory and receivable days further confirm inefficiencies in working capital management. The company should improve its efficiency.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 0.94 | 1.06 | 1.02 | 1.08 | 1.11 |
| Inventory Turnover Ratio | 2.99 | 2.5 | 3.24 | 3.47 | 4.03 |
| Receivables Turnover Ratio | 2.6 | 2.81 | 2.91 | 3.8 | 3.57 |
| Days Sales in Inventory Ratio | 122.07 | 146 | 112.65 | 105.19 | 90.57 |
| Receivable Days | 140.38 | 129.89 | 125.43 | 96.05 | 102.24 |
| Capital Turnover Ratio | 0.7 | 0.83 | 1.23 | 1.05 | 0.99 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The coverage ratios are weak, indicating potential difficulties in meeting interest and dividend obligations. The interest coverage ratio is negative, suggesting an inability to cover interest expenses from earnings. The equity dividend coverage ratio is also low, reflecting limited dividend-paying capacity. The company needs to improve its coverage ratios.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | -0.21 | 0.5 | -3.65 | 1.01 | 0.93 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits strong solvency, with low debt levels relative to equity and assets. The debt ratio and debt-to-equity ratio are low, indicating a conservative capital structure. The equity ratio is high, reflecting a strong equity base. This strong solvency provides financial stability and flexibility but company need to focus on other ratios as well.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.16 | 0.14 | 0.11 | 0.11 | 0.1 |
| Debt to Equity Ratio | 0.19 | 0.16 | 0.12 | 0.12 | 0.11 |
| Equity Ratio | 0.84 | 0.86 | 0.89 | 0.89 | 0.9 |
| Debt To Asset Ratio | 0.1 | 0.09 | 0.05 | 0.06 | 0.06 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The liquidity position is weak, suggesting potential difficulties in meeting short-term obligations. The current and cash ratios are poor, indicating insufficient liquid assets to cover current liabilities. The quick ratio is also low, reflecting limited ability to pay off short-term liabilities without relying on inventory. Improvements are needed to enhance financial flexibility.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.2 | 1.12 | 0.63 | 0.75 | 0.94 |
| Quick Ratio | 0.69 | 0.64 | 0.36 | 0.44 | 0.6 |
| Cash Ratio | 0.04 | 0.01 | 0.01 | 0 | 0.05 |
| Operating Cash Flow Ratio | -0.22 | 0.14 | 0.08 | 0.21 | 0.16 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 33.01 | Overvalued | 58.00 | 6.42 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 77.37 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Windlas Biotech Ltd | 7.52 | 25.92 | Neutral | 105.00 | 32.19 | 66.00 |
| 4 | Lincoln Pharmaceuticals Ltd | 7.31 | 14.01 | Neutral | 98.00 | 43.88 | 88.00 |
| 5 | Morepen Laboratories Ltd | 7.12 | 28.61 | Neutral | 126.00 | 1.21 | 96.00 |
| 6 | Alembic Ltd | 7.06 | 7.28 | Undervalued | 90.00 | 4.85 | 317.00 |
| 7 | NGL Fine Chem Ltd | 6.98 | 39.22 | Overvalued | 73.00 | 67.39 | 48.00 |
| 8 | Syncom Formulations (India) Ltd | 6.92 | 17.27 | Undervalued | 77.00 | 0.81 | 76.00 |
| 9 | Hester Biosciences Ltd | 6.54 | 31.74 | Neutral | 87.00 | 61.24 | 57.00 |
| 10 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 11 | Sakar Healthcare Ltd | 5.81 | 58.66 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 12 | Remus Pharmaceuticals Ltd | 5.31 | 25.48 | Neutral | 57.00 | 20.97 | 46.00 |
| 13 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 27.76 | Undervalued | 269.00 | 4.69 | 138.00 |
| 14 | Indoco Remedies Ltd | 5.26 | -22.79 | Neutral | 142.00 | -0.61 | -99.00 |
| 15 | Ind-Swift Laboratories Ltd | 4.95 | 39.28 | Neutral | 45.00 | 4.89 | 41.00 |
| 16 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 17 | Wanbury Ltd | 4.65 | 28.62 | Neutral | 88.00 | 18.93 | 43.00 |
| 18 | Solara Active Pharma Sciences Ltd | 4.34 | -274.68 | Neutral | 187.00 | -1.50 | -7.00 |
Solara Active Pharma Sciences' management effectiveness shows a mixed performance. While improved operating profit margins signal better operational efficiency, significant concerns arise from declining compounded profit growth and negative returns on capital employed. The decreased promoter holding could indicate a lack of confidence. Overall, the assessment is flagged as Orange, indicating potential challenges that require careful consideration.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Operating Profit Margin (Dec 2024) | 19.21% | Improving OPM indicates better operational efficiency. |
| CONS | Compounded Profit Growth (5 Years) | -66% | Declining profit growth is a significant concern. |
| Return on Capital Employed (Mar 2024) | -9% | Negative ROCE indicates inefficient capital use. | |
| Promoter Holding (Mar 2024) | 30.49% | Decreased promoter holding raises concerns. |
Financial Performance & Growth
Solara Active Pharma Sciences' financial performance indicates revenue and profit challenges. Sales Growth % TTM is at 0%, the compounded sales growth over 5 years is -1%, and over 3 years is 0% portraying lack of revenue expansion. The company's compounded profit growth is also concerning, with a 5-year CAGR of -66%. YOY Profit Growth % shows high volatility, ranging from -5,373% to 168%. The operating profit margin (OPM) has fluctuated significantly, with a recent improvement noted in Dec 2024 at 19.21% but an overall unstable trend.
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Sales Growth % | 166.17% | -4.68% | 22.33% | -21.56% | 13.83% | -10.73% | -0.40% |
| OPM % | 15% | 20% | 24% | 6% | 9% | -7% | 16% |
Capital Efficiency & Returns
The capital efficiency and returns of Solara Active Pharma Sciences are weak. The ROCE% is negative at -9% as of Mar 2024, improving to 6% in Mar 2025 indicating inefficient use of capital. Similarly, ROE is also negative, reflecting poor returns on shareholder funds. The cash conversion cycle is extended, with 120 days in Mar 2024 and 133 days in Mar 2025, suggesting inefficiencies in working capital management.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| ROCE % | 10% | 12% | 15% | -0% | 2% | -9% | 6% |
| Cash Conversion Cycle (Days) | 60 | 101 | 102 | 308 | 252 | 120 | 133 |
Financial Health & Prudence
Solara Active Pharma Sciences' financial health raises solvency concerns. The company carries a significant amount of debt, with total borrowings at ₹796 Cr. as of Mar 2025. Interest coverage has been strained due to low profitability, leading to financial challenges. Dividend payout is inconsistent, with 0% payout in recent years.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Borrowings (₹ Cr.) | 538 | 722 | 621 | 1,037 | 1,013 | 1,012 | 796 |
| Interest Paid (₹ Cr.) | -78 | -79 | -83 | -73 | -87 | -103 | -113 |
| Dividend Payout % | 22% | 5% | 11% | 0% | -49% | 0% | 0% |
Shareholding & Ownership Structure
The shareholding pattern of Solara Active Pharma Sciences has promoter concerns. Promoter holding has decreased from 40.55% in Mar 2019 to 37.94% in Mar 2025. DII holding is low at 2.61% in Mar 2025, indicating limited institutional interest.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Promoter Holding % | 40.55% | 41.88% | 44.11% | 39.71% | 40.98% | 30.49% | 37.94% |
| FII Holding % | 17.36% | 16.41% | 13.65% | 19.42% | 19.30% | 15.80% | 14.63% |
| DII Holding % | 7.10% | 6.87% | 3.98% | 3.64% | 2.75% | 2.97% | 2.61% |
Solara Active Pharma Sciences has high-risk due to its financial performance and operational inefficiencies. Inconsistent profitability, negative ROCE, and high debt levels indicate potential financial strain. Declining promoter holding and fluctuating sales increase these risks. Although some improvements in operating profit margin are noted, the overall risk profile remains concerning.
Segment performance volatility
Quarterly results show volatility in sales and profit growth. YOY Sales Growth % has fluctuated widely, ranging from -46.31% to 41.70%. Similarly, YOY Profit Growth % shows variations, highlighting the inconsistency in profitability. This variability indicates operational and market-related risks.
Foreign exchange or interest rate exposure
The company's financial statements show significant interest expenses, with recent quarterly interest payments around ₹26-31 Cr. Given the fluctuating profitability and high debt levels, Solara Active Pharma Sciences is vulnerable to interest rate fluctuations.
Contingent liability evaluation
Other Income has fluctuated significantly and even been negative in some quarters. In Mar 2024 other income was -185 Cr. and Exceptional items was -189.81.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10565.00Bearish
- SMA 20571.65Bearish
- SMA 50586.10Bearish
- EMA 10566.22Bearish
- EMA 20571.14Bearish
- EMA 50575.41Bearish
- DEMA 10561.95Bullish
- DEMA 20562.95Bullish
- DEMA 50577.65Bearish
- TEMA 10563.06Bullish
- TEMA 20559.04Bullish
- TEMA 50570.06Bearish
- MACD-6.11Bearish
- ADX14.02Weak Trend
- IndicatorValueSignal
- RSI35.57Neutral
- CCI-69.93Neutral
- ROC 9-0.26Bearish
- ROC 14-3.07Bearish
- ROC 25-3.29Bearish
- Stoch K20.80Neutral
- Stoch D15.75Oversold
- IndicatorValueSignal
- BB Upper587.46Neutral
- BB Middle571.65Neutral
- BB Lower555.84Neutral
- ATR6.48Low Volatility
- IndicatorValueSignal
- MFI24.81Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10569.72Bearish
- SMA 20580.98Bearish
- SMA 50569.32Bearish
- EMA 10569.90Bearish
- EMA 20574.77Bearish
- EMA 50570.90Bearish
- DEMA 10562.60Bullish
- DEMA 20571.33Bearish
- DEMA 50582.62Bearish
- TEMA 10560.63Bullish
- TEMA 20562.63Bullish
- TEMA 50580.20Bearish
- MACD-3.74Bearish
- ADX27.84Strong Trend
- IndicatorValueSignal
- RSI40.58Neutral
- CCI-99.65Neutral
- ROC 9-2.67Bearish
- ROC 14-3.33Bearish
- ROC 25-2.92Bearish
- Stoch K12.87Oversold
- Stoch D8.64Oversold
- IndicatorValueSignal
- BB Upper607.83Neutral
- BB Middle580.98Neutral
- BB Lower554.13Neutral
- ATR9.91Low Volatility
- IndicatorValueSignal
- MFI30.70Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10580.18Bearish
- SMA 20575.28Bearish
- SMA 50561.74Bullish
- EMA 10574.35Bearish
- EMA 20572.47Bearish
- EMA 50557.01Bullish
- DEMA 10571.51Bearish
- DEMA 20580.54Bearish
- DEMA 50584.55Bearish
- TEMA 10563.89Bullish
- TEMA 20577.26Bearish
- TEMA 50N/AN/A
- MACD4.96Bearish
- ADX41.67Strong Trend
- IndicatorValueSignal
- RSI47.89Neutral
- CCI-52.12Neutral
- ROC 9-5.91Bearish
- ROC 14-1.62Bearish
- ROC 254.76Bullish
- Stoch K7.80Oversold
- Stoch D19.28Oversold
- IndicatorValueSignal
- BB Upper618.71Neutral
- BB Middle575.28Neutral
- BB Lower531.84Neutral
- ATR17.65Low Volatility
- IndicatorValueSignal
- MFI59.35Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 10576.94Bearish
- SMA 20560.81Bullish
- SMA 50530.08Bullish
- SMA 100502.25Bullish
- SMA 200546.73Bullish
- EMA 10572.87Bearish
- EMA 20563.14Bearish
- EMA 50537.98Bullish
- EMA 100527.64Bullish
- EMA 200536.92Bullish
- DEMA 10580.02Bearish
- DEMA 20582.84Bearish
- DEMA 50564.84Bearish
- DEMA 100527.03Bullish
- DEMA 200516.48Bullish
- TEMA 10576.41Bearish
- TEMA 20582.64Bearish
- TEMA 50588.36Bearish
- TEMA 100549.75Bullish
- TEMA 200505.57Bullish
- MACD14.17Bearish
- ADX43.46Strong Trend
- IndicatorValueSignal
- RSI52.18Neutral
- CCI10.45Neutral
- ROC 142.87Bullish
- ROC 2510.91Bullish
- Stoch K50.47Neutral
- Stoch D59.98Neutral
- IndicatorValueSignal
- BB Upper606.79Neutral
- BB Middle560.81Neutral
- BB Lower514.82Neutral
- ATR28.58Low Volatility
- IndicatorValueSignal
- MFI82.96Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 20498.49Bullish
- SMA 50559.81Bullish
- EMA 20525.17Bullish
- EMA 50538.52Bullish
- DEMA 20526.20Bullish
- DEMA 50519.63Bullish
- TEMA 20548.50Bullish
- TEMA 50500.60Bullish
- MACD5.41Bullish
- ADX21.84Weak Trend
- IndicatorValueSignal
- RSI57.58Neutral
- CCI25.43Neutral
- ROC 1432.57Bullish
- ROC 256.06Bullish
- Stoch K71.83Neutral
- Stoch D69.22Neutral
- IndicatorValueSignal
- BB Upper586.49Overbought
- BB Middle498.49Neutral
- BB Lower410.49Neutral
- ATR53.77High Volatility
- IndicatorValueSignal
- MFI90.01Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6497.90Bullish
- SMA 12549.69Bearish
- SMA 24584.91Bearish
- EMA 6507.34Bullish
- EMA 12525.25Bullish
- EMA 24536.29Bearish
- DEMA 6491.89Bullish
- DEMA 12502.16Bullish
- DEMA 24524.94Bullish
- TEMA 6499.10Bullish
- TEMA 12480.63Bullish
- TEMA 24532.09Bullish
- MACD-6.10Bearish
- ADX13.05Weak Trend
- IndicatorValueSignal
- RSI50.17Neutral
- CCI37.36Neutral
- ROC 258.53Bullish
- ROC 50-13.21Bearish
- Stoch K36.31Neutral
- Stoch D53.80Neutral
- IndicatorValueSignal
- BB Upper779.49Neutral
- BB Middle568.66Neutral
- BB Lower357.83Neutral
- ATR116.32Low Volatility
- IndicatorValueSignal
- MFI74.43Neutral